BioStock: PolarCool Q4 performance improved in 2021

PolarCool’s Q4 report reflects the significant investments made in clinical validation of its concussion treatment device, PolarCap System. Those investments starting to pay off as net sales during the period have doubled compared to the same period last year. PolarCool expects those numbers to continue to increase in the months to come as more licensing agreements are made. BioStock spoke with CEO Erik Andersson to get his take.

Read the interview with Erik Andersson at biostock.se:

https://www.biostock.se/en/2022/02/polarcool-q4-performance-improved-in-2021/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se